AstraZeneca’s Failed Wainua Trial Raises Concerns Over Pipeline Valuation Premium
AstraZeneca's recent failure in a late-stage trial for its drug Wainua has raised concerns about the company's overall pipeline valuation, despite analysts estimating only a modest financial impact. The market's reaction suggests a reassessment of investor confidence in AstraZeneca's ability to deliver successful drug developments.